Market Intelligence, Preclinical Progress, and High-Purity Reagents for CNS, Epilepsy & Pain Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CACNG8 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | CACNG8 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Sequence Verified. |
View CACNG8 Products |
| Antigen (Full-Length Lentivirus) | CACNG8 Full-Length Lentivirus Particles HEK293 expressed, native conformation, Endotoxin <1EU/ug. High titer (>10^8 TU/mL), Puromycin selectable. |
View CACNG8 Products |
| Antigen (Recombinant Protein) | CACNG8 Recombinant Protein (Partial ECD) High purity (>95%), Endotoxin <1EU/ug. |
View CACNG8 Products |
| Benchmark Antibody | Anti-CACNG8 Control Antibody Recombinant positive control for expression validation (Flow Cytometry/WB). |
View CACNG8 Products |
| Validator | CACNG8 siRNA Set For knockdown verification and specificity controls (≥3 independent sequences, >80% efficiency). |
View CACNG8 Products |
| Related Target A | GRIA1 (GluA1) AMPA receptor pore subunit; primary functional binding partner for CACNG8 interaction studies. Co-expression required for functional assays. |
View GRIA1 Products |
| Related Target B | GRIA2 (GluA2) AMPA receptor subunit 2; critical for calcium permeability modulation. |
View GRIA2 Products |
| Related Target C | CACNG2 (Stargazin) TARP family prototype; reference standard for selectivity counter-screening. |
View CACNG2 Products |
| Related Target D | CACNG3 (TARP gamma-3) Neuronal-specific TARP; comparative target for CNS selectivity screening. |
View CACNG3 Products |
| Related Target E | CACNG4 (TARP gamma-4) Additional TARP member for comprehensive selectivity panel. |
View CACNG4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Four Transmembrane Domain Topology Preservation | Pre-made Lentiviral Particles for Stable Cell Line generation; preserves native membrane insertion, glycosylation patterns, and extracellular loop orientation |
| AMPA Receptor Functional Coupling | Co-expression compatible vectors (e.g., bicistronic); HEK293 background for mammalian post-translational modification fidelity |
| Cross-species Translation (Human/Rat/Mouse) | Ortholog ORF clones with matched vector backbones; verified TM domain alignment (>90% identity) |
| Specificity vs. TARP Family Members | Homolog panel (CACNG2/3/4) for counter-screening; strictly sequence-verified by mass spec |
| Lack of Expression Controls | Benchmark Recombinant Antibodies available for reliable Flow Cytometry/WB validation |
| False Positives in Functional Assays | Validated siRNA sets included for robust genetic specificity checks; knockdown efficiency >80% |
Live CACNG8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
CACNG8 (TARP gamma-8) represents an emerging frontier in CNS drug discovery, with increasing recognition of its role in AMPA receptor trafficking and kinetics modulation. While still in preclinical stages for most therapeutic applications, the target has gained traction following GWAS associations with schizophrenia and bipolar disorder. The race for selective TARP-targeted therapeutics is intensifying, with major players like Eli Lilly and Cerevel/J&J shifting focus from traditional broad-spectrum AMPA blockers to highly selective negative allosteric modulators (NAMs) for focal epilepsy and cognitive deficits. Current R&D activity also includes small molecule positive allosteric modulators (PAMs) for cognitive impairment, peptide disruptors for chronic pain, and antibody drug discovery for pain management. As the field moves toward selective TARP-targeted therapeutics, the demand for high-fidelity cell-based assays that preserve the four-transmembrane architecture has become the critical bottleneck in lead optimization.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Allosteric Modulators (NAMs, PAMs) | Eli Lilly, Cerevel/J&J, Academic consortia, Early-stage biotech | Schizophrenia, Cognitive impairment, Focal epilepsy, Temporal lobe epilepsy | Selectivity Assay (Need CACNG8 vs CACNG2 stable cell lines); Calcium flux with precise stoichiometry; Lentivirus for GRIA/CACNG co-expression |
| Peptide Disruptors | Specialized CNS platforms | Chronic pain, Epilepsy | Co-expression systems with GRIA1; Sequence-verified full-length CACNG8 for binding validation |
| Antibody Drug Discovery | Emerging | Pain management | Cell-based immunization targets; Membrane-embedded antigen presentation via stable transduction |
| Biologic (mAb/Peptide) | Early-stage CNS biotech | Intractable epilepsy | Native conformation epitope mapping (Need full-length cell lines) |
| Gene Therapy / ASO | Gene therapy platforms | Rare neurodevelopmental disorders, Refractory seizures | Target engagement (Need highly specific anti-CACNG8 Abs); Promoter-compatible ORF Lentivirus |